ProCE Banner Activity

Questions Answered on ART Safety and Tolerability in Aging Patients and Populations With Cardiometabolic Toxicities

Podcast Episodes

Hear from expert faculty as they answer questions and discuss key considerations when evaluating potential ARV-related toxicities in special populations, including aging patients and populations with cardiometabolic toxicities.

Released: January 17, 2023

Expiration: January 16, 2024

Share

Faculty

Marta Boffito

Marta Boffito, MD, PhD, FRCP, MBA

Consultant Physician
Clinical Director
HIV, Sexual and Gender Health, Dermatology
Chelsea and Westminster Hospital NHS Foundation Trust
Imperial College London
London, United Kingdom

Jens D. Lundgren

Jens D. Lundgren, MD, DMSc

Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Janssen Therapeutics, Division of Janssen Products, LP

ViiV Healthcare

Faculty Disclosure

Primary Author

Marta Boffito, MD, PhD, FRCP, MBA

Consultant Physician
Clinical Director
HIV, Sexual and Gender Health, Dermatology
Chelsea and Westminster Hospital NHS Foundation Trust
Imperial College London
London, United Kingdom

Marta Boffito, MD, PhD, FRCP: consultant/advisor/speaker: Cipla, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp and Dohme, ViiV Healthcare; researcher: Novavax, Roche, Valneva.

Jens D. Lundgren, MD, DMSc

Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark

Jens D. Lundgren, MD, DMSc, has no relevant financial relationships to disclose.